Allogene Therapeutics Set for December Investor Engagements
Allogene Therapeutics, Inc. (Nasdaq: ALLO), renowned for its innovative work in developing allogeneic CAR T (AlloCAR T™) therapies, has announced its participation in two significant investor conferences this December. This reflects the company's commitment to advancing cancer and autoimmune disease treatments, making its cutting-edge research available to a broader audience.
Upcoming Conference Details
The first event on the agenda is the Citizens JMP Hematology and Oncology Summit, which will occur virtually on December 2. Investors can expect engaging discussions starting at 8:00 AM PT, or 11:00 AM ET. Following closely, the 36th Annual Piper Sandler Healthcare Conference will take place on December 3 at 5:00 AM PT, offering an excellent opportunity for stakeholders to gain deeper insights into Allogene's strategic direction.
Time Update for Jefferies London Healthcare Conference
In addition to the December events, Allogene has also updated the timing for their participation in the Jefferies London Healthcare Conference scheduled for November 20. The new presentation time is set for 11:30 AM GMT, which translates to 6:30 AM ET. This adjustment ensures potential investors and stakeholders can plan accordingly to engage with Allogene's team effectively.
Accessing Webcasts and Updates
Investors and interested parties can find any available webcasts of these conferences on the company’s official website under the Investors tab in the News and Events section. Following each live presentation, a recording will remain accessible for approximately one month, providing ample time for review and understanding of the discussions presented.
About Allogene Therapeutics
Allogene Therapeutics is at the forefront of biotechnology with headquarters in South San Francisco. The company specializes in developing allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies designed for treating cancer and autoimmune diseases. With a robust management team possessing extensive experience in cell therapy, Allogene is focused on creating a pipeline of “off-the-shelf” CAR T cell products. This approach aims to provide readily accessible cell therapies on-demand, enhancing reliability and scalability to treat more patients effectively.
Innovations in CAR T Cell Therapies
The AlloCAR T™ technology represents a breakthrough in improving cancer treatment accessibility. By offering a ready-to-use solution, Allogene is set to transform the therapeutic landscape, ensuring that effective treatments reach those in need without the delays often associated with traditional methods. Their commitment to refining these techniques underscores their vision of making advanced medical care widely available.
Continued Commitment to Progress
As Allogene Therapeutics continues to thrive in the competitive biotech sector, their focus on innovation, patient-centric solutions, and collaboration with healthcare professionals is evident. The active participation in influential conferences demonstrates their proactive approach to sharing advancements and engaging with key stakeholders.
Stay Informed
For further details on Allogene's initiatives, including their participation in upcoming events and latest updates, interested individuals are encouraged to follow Allogene Therapeutics on X and LinkedIn. Keeping an eye on their social media pages can provide valuable insights into ongoing developments and future plans.
Frequently Asked Questions
What is the primary focus of Allogene Therapeutics?
Allogene Therapeutics focuses on the development of allogeneic CAR T therapies aimed at treating cancer and autoimmune diseases.
When are the upcoming investor conferences?
The upcoming conferences are scheduled for December 2 and December 3.
How can one access the webcasts of the conferences?
Webcasts will be available on Allogene's official website under the Investors tab in the News and Events section.
What does AlloCAR T™ signify?
AlloCAR T™ is a trademark for Allogene's innovative CAR T therapies, highlighting their unique approach to treatment.
How can I keep updated on Allogene's news and events?
Follow Allogene Therapeutics on social media platforms like X and LinkedIn for the latest news and updates.
